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Abstract 
Human African Trypanosomiasis (HAT) also called sleeping sickness is caused 
by subspecies of the parasitic hemoflagellate Trypanosoma brucei that mostly 
occurs in sub-Saharan Africa. The current chemotherapy of the human 
trypanosomiases relies on only six drugs, five of which have been developed 
more than 30 years ago, have undesirable toxic side effects and most of them 
show drug-resistance.  Though development of new anti-trypanosomal drugs 
seems to be a priority area research in this area has lagged far behind. The 
given review mainly focus upon the recent synthetic and computer based 
approaches made by various research groups for the development of newer 
anti-trypanosomal analogues which may have improved efficacy and oral 
bioavailability than the present ones. The given paper also attempts to 
investigate the relationship between the various physiochemical parameters 
and anti-trypanosomal activity that may be helpful in development of potent anti-
trypanosomal agents against sleeping sickness. 
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Introduction 
African sleeping sickness remains one of the most neglected life threatening diseases that 
have been left untreated till date. Two forms of human African trypanosomiasis (HAT) 390  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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have  been identified  that are parasite dependent.  The first one Trypanosoma brucei 
gambiense (T. b. gambiense) causes a human chronic infection, endemic in Western and 
Central Africa while the other Trypanosoma brucei rhodesiense (T. b. rhodesiense) has a 
vast animal reservoir and causes acute illness in people in eastern and Southern African 
countries. HAT has high occurance in the remote rural areas, where the surveillance is 
weak or nonexistent, with 50 to 70 thousand estimated cases. According to World Health 
Organization (WHO) estimation there are half-million cases of HAT or "sleeping sickness" 
resulting from infections with T. brucei rhodesiense and T. brucei gambiense. WHO has 
attributed 50.000  deaths annually to the disease [1].  By more recent estimates, up to 
25.000 new cases occur per year, and 50 million people are at risk [2, 3]. 
Out of six clinically approved drugs for the treatment of HAT, five (suramin, pentamidine, 
melarsoprol, eflornithine and nifurtimox) have had been discovered more than 30 years 
ago. Because suramin and pentamidine are ionized at physiological pH, they are unable to 
cross the blood brain barrier in therapeutic concentrations and are thus used for the 
treatment of hemolymphatic early stage HAT, caused by T. b. rhodesiense  and  T. b. 
gambiense  infections, respectively. The treatment of the second or neurological stage, 
when the parasites invade the central nervous system (CNS), relies on the organo-
arsenical drug melarsoprol and the more recently registered eflornithine. The latter is 
ineffective against T. b. rhodesiense  sleeping sickness and is used primarily to control 
CNS-involved HAT caused by T. b. gambiense. All the existing anti-trypanosomal 
therapies suffer from unacceptable toxicity, poor efficacy, difficulties of administration, and 
increasing treatment failures due to the development of parasite resistance [4–9]. In the 
last couple of decades, no new drug has been developed for treatment of early-stage HAT, 
and only one drug has been developed for late-stage HAT [1, 3, 5]. The need is great for 
new orally active drugs for the control and eradication of this disease.  
Novel medicines are typically developed using a trial-and-error approach, which is time-
consuming and costly  but yet has the potential to yield new drugs. The application of 
computer-assisted drug design (CADD) methodologies to this problem has the potential to 
greatly decrease the time and effort required to discover new medicines or improve current 
ones in term of their efficacy. 
This review focuses  on the synthetic and computer-assisted drug design (CADD) 
approaches made by various research groups for the development of newer anti-
trypanosomal agents having improved efficacy and oral bioavailability. The current 
research also endeavors [10] to investigate the relationship between the various physio-
chemical parameters and anti-trypanosomal activity that may be helpful in development of 
potent anti-trypanosomal agents against sleeping sickness. 
Synthetic advances 
Safe, effective and affordable orally active therapies for trypanosomiasis  capable of 
overcoming resistance are required, so the identification of new anti-trypanosomal drug 
candidates is an urgent priority. Compared to the last 15 years there has been a revival of 
drug research and development regarding neglected parasitic diseases, and a number of 
drug development projects are currently ongoing [11]. In view of this, the researchers have 
endeavored to compile in the present section of the review, diverse series of compounds 
that have been recently synthesized by various research groups targeting DNA minor   Neglected Disease – African Sleeping Sickness: Recent Synthetic and Modeling Advances  391 
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groove and many other new targets. Based on the mechanism of action this section has 
been divided into two sub-sections. The first sub-section includes the series of compounds 
acting as DNA minor groove binders while in the second sub-section are included all the 
other anti-trypanosomal compounds and their respective targets. Also are  described 
herein prodrug approaches to provide oral bioavailability for the dication class. 
DNA minor groove binders 
The wide range of antifungal and antiparasitic activities related to aromatic diamidines and 
its excellent results in preclinical and clinical phase of drug development has made 
aromatic diamidines an interesting class for the development of newer anti-trypanosomal 
drug therapy. The aromatic diamidines i.e. pentamidine (Figure 1) show their anti-parasitic 
action by binding strongly to AT-rich sequences in the minor groove of DNA. Therefore 
DNA minor groove has evolved as a productive target for designing new ant-parasitic 
drugs. In order to design newer analogues belonging to diamidine series, studies of the 
DNA complexes with diamidine compounds have been conducted  and a number of 
diamidines have been crystallized with the DNA duplex d(CGCGAATTCGCG)2 which 
provide valuable models for drug development in the diamidine series. Structures of DNA 
complexes of furamidine, berenil, and pentamidine, for example, reveal that they all bind in 
the DNA minor groove at the central AATT sequence. These drugs penetrate deeply into 
the groove and fit snugly between the walls of the groove. Their amidines form H-bonds 
with thymine-O2 and/or adenine-N3 acceptor groups on the edges of the bases at the floor 
of the groove. The amino group of G protrudes into the minor groove and prevents the 
compounds from assuming their preferred orientation deep in the minor groove.  This 
binding to DNA eventually leads to inhibition of one or more of the several DNA-dependent 
enzymes (e.g., topoisomerases and nucleases) or direct inhibition of transcription. 
For more than 50 years aromatic diamidines and related dicationic molecules have been 
extensively used but so far only pentamidine [12–15] has been widely employed as a drug 
in humans despite several adverse effects, such as hypotension, abdominal pain, vertigo, 
hypersalivation, hypoglycemia, nausea, and mild nephrotoxocity [5–8]. Being a highly 
flexible molecule that can assume an array of linked conformations related through 
torsional rotation, changes can be made in the nucleus to produce improved analogous 
against HAT. In line to this with an aim to increase the efficacy and decrease the side 
effect related to pentamidine various research groups have made several changes in the 
pentamidine molecule [16–23] to develop newer compounds having same or enhanced 
pharmacological activity. The newer analogues of pentamidine that have been recently 
synthesized are:  
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Fig. 1.   Structure of Pentamidine 
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Fig. 2.  Structures of various congeners of pentamidine synthesized by modification in 
parent pentamidine molecule   Neglected Disease – African Sleeping Sickness: Recent Synthetic and Modeling Advances  393 
Sci Pharm. 2011; 79: 389–428 
Pentamidine analogues 
Large numbers of structurally related congeners of pentamidine were synthesized by 
Tidwell RR et al [24] by introducing substitutions on the cationic groups, changing the 
position of dications from 4,4' to 3,3' position, changing the length of the aliphatic chain 
between the two aromatic rings, adding substituent on the aromatic rings at 2,2' and 3,3' 
position and replacing oxygen atoms in the alkyl linker with isosteric sulfur or nitrogen 
atoms (Figure 2a–g). On comparing the activities of the synthesized compounds with 
pentamidine and melarsoprol, it was found that few compounds showed activity in the 
range or better than that of pentamidine and/or melarsoprol. The unsubstituted diamidine 
compound 64 (Figure 3a) with secondary amino group in place of oxygen atom exhibited 
subnanomolar activity (<0.001 µM) against T. b. rhodesiense  and was nearly twice as 
selective against the pathogen as pentamidine. At the same time the diimidazoline 
compound 66 (Figure 3b) exhibited the second highest anti-trypanosomal activity in the 
series with the IC50 value of 0.001 µM and also had the highest parasite selectivity (SIT= 
34500), being 63 times more selective against T. b. rhodesiense than pentamidine. The 
replacement of oxygen atom with sulphur atom as in compound 62 (Figure 3c) also 
generated active congeners having IC50 (0.005 µM) value better than that of pentamidine 
(0.007 µM). The compounds 20–31 (Figure 2c) in which the cationic groups were present 
in the 3,3′-position of the aromatic rings and the length of the carbon linker was varied from 
3–6 exhibited lower anti-trypanosomal activity compared to pentamidine whereas among 
the compounds 12–19 (Figure 2b) of the series, in which the amidine groups were present 
at 4,4' position and the length of aliphatic chain was varied from three carbon atoms to six 
carbon atoms, compound 12 (Figure 3d, IC50=0.007 µM) with three methylene linker 
between the aromatic rings had same in vitro activity as that of pentamidine (0.007 µM). 
Further  introduction  of  2,2′-dichloro substituent in compound 12 improved the anti-
trypanosomal properties as evident from the in vitro activity of compound 32 (Figure 3e, 
IC50=0.004 µM).  
These compounds having excellent in vitro activity were evaluated in vivo in the STIB900 
mouse model of African trypanosomiasis. The screening was conducted using 
intraperitoneal dosing at 20 mg/kg daily for four days. The compounds 12, 62 and  64 
showed very poor in vivo activity, whereas compound 32 and 66 exhibited excellent in vivo 
efficacies in the acute mouse model of trypanosomiasis, providing cures of all infected 
animals. 
Thus, because of high selectivity, excellent in vitro and in vivo activity compounds 66 and 
32 can serve as a novel lead for further pre-clinical and clinical trials, but its cytotoxcity 
profile needs to be monitored during its evaluation. Also compound 64 which showed 
excellent in vitro, in vivo activity and high selectivity index against the T. b. rhodesiense 
merits  further SAR optimization in order to synthesized newer lead compounds with 
reduced cytotoxicity compared to pentamidine. 
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Fig. 3.   Pentamidine analogues with activity better than that of melarsoprol and/or 
pentamidine 
Pyridyl analogues of Pentamidine 
Increased efficacies of pyridyl analogues of 2,5-bis(4-amidinophenoxy)furan (furamidine) 
[25–27] encouraged Tidwell RR et al [28] to synthesize pentamidine analogues in which 
the phenyl rings of pentamidine were replaced with pyridyl fragments. This replacement 
resulted in series of 18 compounds (Figure 4a), most of which had lower cytotoxicity than 
pentamidine. SAR study pointed out that the antiprotozoal properties of these compounds 
depended on the placement of cationic moieties on the pyridine rings as well as the nature 
of substituents on the amidine groups. The N-substituted congeners were lesser cytotoxic 
than the unsubstituted diamidines whereas the N-alkylation of cationic fragments reduces 
the activity of compounds against T. brucei rhodesiense  compared to pentamidine. A 
same trend was observed in pentamidine analogues series. The 2, 6-substituted dications 
(compounds 11–13, figure 4a) and 2,4-substituted dications (compounds 14–18, figure 4a) 
displayed lower potencies against T. brucei rhodesiense  than  the corresponding 
2,5-substituted isomers (compounds 1–10, figure 4a), while among the 2, 5-substituted 
dications, the compounds possessing cationic substituents adjacent to nitrogen atoms in 
pyridine rings displayed superior activities against parasites compared to pentamidine as 
evident from compound 6 (figure 4b) which showed promising anti-trypanosomal activity 
(0.001µM) and lower cytotoxicity (4.90µM) than pentamidine and melarsoprol, but had 
poor  in vivo  activity giving only  1/4 cures in the STIB900 mouse model.  However 
diamidoxime compound 9 (Figure 4c), an oral prodrug of diamidine compound 6 (Figure 
4b), exhibited excellent in vivo  activity curing four out of four animals upon oral 
administration in STIB900 mouse model. Although compound 9 did not provide cure in the   Neglected Disease – African Sleeping Sickness: Recent Synthetic and Modeling Advances  395 
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CNS mouse model of infection but its BBB permeability could potentially be improved by 
developing prodrug using lipophillic substitutions in place of hydrophilic substitution as 
used in compound 9. This could provide higher concentration of compound 6 in CNS.  
Thus excellent in vitro  activity of diamidine 6 and high in vivo  efficacy of its prodrug 
diamidoxime 9 warrant further investigation of these dications as potential anti-
trypanosomal drug candidates with improved oral efficacies. 
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Comparison of two most potent pentamidine analogues: compound 6 (Figure 4b) and 
compound 66 (Figure 3b) 
The structure activity relationship of the two series indicates that in both the cases the 
unsubstituted diamidines were more active than the N-substituted diamidines. The 
replacement of oxygen atoms in alkyl chain with secondary amino group improves the 
activity against T. b. rhodesiense  of pentamidine analogues while in case of pyridyl 
analogue the compounds with oxygen atoms in the alkyl chain have been the active one. 
The most potent compound of these two series are compound 6 (Figure 4b) and 
compound 66 (Figure 3b), which have excellent in vitro activity (0.001µM) better than 
pentamidine and melarsoprol and also have high selective against the T. b. rhodesiense 
parasite as evident from their selectivity index (SI of compound 6 = 4900 and compound 
66 = 34500 µM). Initially it has been believed that the oxygen atom in the aliphatic linker 
and the amidine groups are important for anti-trypanosomal activity of pentamidine as 
these groups were part of recognition motif for P2 amino purine transporter in 
trypanosoma species. Thus the activity of compound 6 can be explained on this basis, but 
in case of compound 66 the amidine groups have been replaced by imidazoline and the 
oxygen atom has been replaced by secondary amino groups. Despite these replacements, 
the compound has shown excellent in vitro and in vivo activity. Thus this is in accordance 
to recently reported work [29] according to which there is no direct connection between the 
affinity for P2 carrier and anti-trypanosomal activity. 
In view of this, these two compounds can serve as a lead structure for the development of 
newer analogues of pentamidine with reduced side effect and improved pharmacokinetic 
profile. 
Benzofuran derivatives 
In the early 1970s Dann O et al [30–32] reported the anti-trypanosomal properties of two 
bisbenzofuran diactions (Figure 5a & 5b) and two phenylbenzofuran (Figure 6a & 6b), but 
since then these compounds received very little attention. However recently lead 
optimization study of these dications had been carried out by Tidwell RR et al, who have 
synthesized and reported the in vitro, in vivo activities and cytototixicity of about 43 
dicationic bisbenzofuran derivatives (Figure 7a) [33] as heterocyclic pentamidine 
analogues in which phenoxy fragments were included into a benzofuran structural motif, 
Tidwell RR et al also synthesized a series of 49 diactionic 2-phenylbenzofuran derivatives 
(Figure 8) [34]. 
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Fig. 7.  (a) Structure of the basic nucleus of bisbenzofuran and the various substituition 
used to synthesized 43 congeners.  
(b) stucture of compound with low cytotoxicity 
a) Dicationic bisbenzofuran derivatives 
Tidwell RR  et al found that the in vitro anti-trypanosomal activities of bisbenzofuran 
derivatives against Trypanosoma brucei rhodesiense, and cytotoxicity against mammalian 
cells depended on the position and the type of cationic substituents as well as the length of 
the carbon linker between aromatic moieties.  As observed in most of the dicationic 
molecules, the N-substituted congeners were lesser cytotoxic than the unsubstituted 
diamidines  whereas  the N-alkylation of cationic fragments reduced the activity of 
compounds against T. brucei rhodesiense compared to pentamidine. At same time the 
5-substituted bisbenzofurans were generally less cytotoxic than compounds bearing 
substituents in the 4-  or 6-positions where as the 4-substituted bisbenzofurans were 
significantly less active against T. b. rhodesiense than corresponding 5- and 6-substituted 
isomers. The in vitro activity of the bisbenzofuran series was not so promising and only 
lead compound 8, (Figure 5b) exhibited in vitro anti-trypanosomal activity (0.008 µM) 
comparable to that of pentamidine and melarsoprol.  However some compounds from 
Tidwell series (Figure 7b) showed reduced cytotoxicity profile compared to pentamidine 398  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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(for example compound 43 has cytotoxicity of 1.85 µM), but had very poor selectivity 
profile. Thus was proved that the selectivity of bisbenzofurans against T. b. rhodesiense 
decreases as number of methylene groups in the alkyl bridge increases.  
However, how the substitution on the amidine groups affects the anti-trypanosomal 
properties of bisbenzofurans has not been explained.  Thus in light of their reduced 
cytotoxicity compared to pentamidine these molecules require further investigation to study 
the influence of the type of cationic substituents and the distance between aromatic 
moieties on uptake and intracellular distribution of dicationic bisbenzofurans in order to 
understand better the mode of action and thus improve the efficacy of aromatic 
diamidines. 
b) Cationic 2-phenylbenzofuran derivatives 
Tidwell RR  et al synthesized and evaluated the activity of 49 dicationic 2-phenyl-
benzofurans derivatives (Figure 8) against Trypanosoma brucei rhodesiense. Six 
compounds (Figure 9) among the series including lead compound 1 (Figure 6a) exhibited 
excellent in vitro and in vivo anti-trypanosomal activity and were highly selective for the T. 
b. rhodesiense parasite. All the six active compounds contained diamidine groups, which 
clearly suggested that diamidines exhibited higher anti-trypanosomal activities compared 
to di(N-isopropyl)amidines and diimidazolines. The 5,-substituted dicationic compounds 29 
(IC50=0.002 µM, Figure 9e) and 32 (IC50=0.002 µM, Figure 9c) showed better anti-
trypanosomal activity than the 6-substituted dicationic compound 38 (IC50=0.003 µM, 
Figure 9d). Whereas among the 5,5' substituted diamidines and 5,4' substituted diamidine, 
selectivity against the parasite of 5,5′-substituted dications was higher than 5,4′-substituted 
congeners. Introduction of the hydroxy substituents in the 7-or 2′-position of compound 1 
(Figure 6a) resulted into compound 20 (Figure  9a)  and compound 32  (Figure 9c)  with 
enhanced anti-trypanosomal activity and higher selectivity against T. b. rhodesiense. 
These dicationic compounds were further evaluated in  the STIB900 animal model of 
African trypanosomiasisn. Only compounds 1, 32 and 20 showed exclellent in vivo activity 
providing 3/4 and 4/4 cures respectively when administered intraperitoneally. 
Thus promising in vitro, anti-trypanosomal activity, excellent potency in the acute mouse 
model of trypanosomiasis and the reduced cytotoxicity (1.9 µM) of compound 1 compared 
to pentamidine warrants further pre-clinical and clinical trials of this molecule. While 
compound 32 and 20 can serve as lead compounds for further SAR optimization to derive 
congener with enhanced activity and lesser cytotoxicity. 
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Fig. 9.   Structures of compounds with promising anti-trypanosomal activity 
c) Pentamidine congeners bearing the benzofuran motif 
To combine the rigidity of 2-phenylbenzofurans with the flexibility of pentamidine 
congeners,  Tidwell RR  et al [35] incorporated the benzofuran ring into molecules of 
pentamidine-related analogues. A series of 48 pentamidine congeners containing 
benzofuran fragments (Figure 10a, b) were synthesized and tested in vitro against T. b. 
rhodesiense. Most of the compounds in the series showed cytotoxicity less than that of 
pentamidine, but had lesser potency and selectivity index as compared to pentamidine. 
The properties and cytotoxicities of these dications depended on the nature of the cationic 
substituents, the placement of the benzofuran motif, and the length of the carbon linker. 
Within the series cytotoxicity of the compounds decreased with the substitution on cationic 
groups and increased with the elongation of the carbon linker.  
Dications with the benzofuran motif in the 4'-position (compounds 25–48, Figure 10b) and 
connected by the propylene linker are the most potent and more selective against T. b. 
rhodesiense among the series. Thus on the basis of SAR study further improvements can 
be made in order to produce newer anti-trypanosomal agents with improved pharma-
cological activity.  400  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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Fig. 10.  Structures of pentamidine congeners bearing the benzofuran motif  
Comparision of Benzofuran derivatives 
The SAR of the three series clearly indicates that the nature of cationic substituents and 
their position is important in deciding the anti-trypanosomal activity of benzofuran 
derivatives. The introduction of phenoxy fragment into a benzofuran structural motif may 
result into retention of affinity for the aminopurine P2 transporter, which could be the 
reason for anti-trypanospomal activity of benzofuran derivatives. However the precise 
mechanism by which these compounds show their anti-trypanosomal activity in not known. 
Among the three series the 2-phenylbenzofuran derivatives are attractive molecules 
because of their high activity, low cytotoxicity and high selectivity against the HAT parasite. 
The introduction of phenoxy fragment into the aromatic ring protects the phenylbenzofuran 
dervatives from metabolic deactivation. This structural modification retains affinity for the 
aminopurine P2 transporter. The diamidine and the hydroxy or methoxy group may be 
involved in binding to the DNA minor groove. Thus multiple modes of action may be the 
reason for promising anti-trypanosomal propertries of 2-phenylbenzofuran derivatives. 
Thus  these  compounds require further assessment in order to develop as newer anti-
trypanosomal agents with promising pharmacokinetic profile. 
Furamidine compounds 
Since a prodrug of furamidine, 2,5-bis[4-(N-methoxy)amidinophenyl]furan (pafuramidine), 
has shown promising results in clinical trials against HAT [36], therefore Furamidine 
(Figure 11a) has gained attention for further evaluation to produce newer anti-
trypanosomal analogous. Two other analogues of furamidine (Figure 11b &c) have been 
evaluated against T. b. rhodesiense mouse model and have shown promising results. One   Neglected Disease – African Sleeping Sickness: Recent Synthetic and Modeling Advances  401 
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approach to enhance the activity of furamidine has been the replacement of the central 
furan ring with other heterocyclic systems, including thiophene, pyrrole, oxazole, 
oxadiazole, thiadiazole, pyridazine, methylpyrimidine, and triazine [37–41]. Such structural 
modification in past has resulted into compound with good anti-parasitic activity. For 
example in 1977 Boykin DW and Das PB have reported the synthesis and antiprotozoal 
activity of eighteen substituted 2,5-bis(4-guanylphenyl)furans and related analogues, 
including  "masked"  amidines in which the guanyl function was incorporated into a 
heterocyclic ring. Among these, six compounds have  produced cures in mice at 
submilligram dosage levels and  have been somewhat more active in this screen than 
stilbamidine, hydroxystilbamidine, and pentamidine. In 1994 Boykin DW et al have 
reported the synthesis of dicationic diaryltriazines nucleic acid binding agents, while in 
year 1998 Boykin DW et al have also reported the anti-Pneumocystis carinii pneumonia 
activity of dicationic diaryl methylprimidines. Dann O et al in the year 1975 have reported 
that 3,5-bis(4-amidinophenyl)isoxazole (Figure 13b) which is the most structurally similar to 
furamidine, is reported to have high activity against a murine T. brucei rhodesiense modelc 
[42]. However most of these compounds have received very little attention since. Recently 
the optimization of the few of the compounds has been reported and as a result several 
lead compounds have been synthesized. Here in are listed some of the compounds.  
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Fig. 11.   Structure of furamidine and its analogue that have shown promising anti-
trypanosomal properties 
a) Dicationic 3,5-diphenylisoxazoles 
Tidwell RR et al [43] has recently synthesized a series of 3,5-diphenylisoxazole analogues 
(Figure 12), in which the central ring of furamidine was replaced by isoxazole, and their 
activities with furamidine and melarsoprol  were compared. Among 43 synthesized 402  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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dications, the compounds with at least one p-amidine moiety (compound 22, Figure 13a 
and compound 3, Figure 13b), displayed good IC50  values (3.5 nM and 5.1 nM 
respectively) comparable to that of furamidine (4.3 nM) while loss in potency was observed 
in compounds with substituted diamidine at m-position (compound 32, IC50=29 nM, Figure 
13c). In general, the introduction of nitro, chloro, or methoxy substituents on either 
aromatic ring resulted in decreased anti-trypanosomal activity. However, the introduction 
of methoxy group on the aromatic rings of compound 32 resulted into compound 41 
(Figure 13b) with comparable anti-trypanosomal activity (4.2 nM) as that of furamidine. 
Hence these compounds of the isoxazole series that showed good in vitro anti-
trypanosomal activity and less cytotoxcity profile relative to furamidine, could be a 
candidate for further evaluation against animal models of the diseases.  
However in vivo evaluation of the present 3,5-diphenylisoxazole series has not been 
reported yet.  
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Fig. 12.   The basic nucleus and the various substitutents used for the synthesis of 43 
dicationic 3,5-diphenylisoxazoles 
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Fig. 13.   Stuctures of selected dicationic 3,5-diphenylisoxazole derivatives 
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b) Cationic 1,4-diphenyl-1H-1,2,3-triazoles 
The excellent anti-trypanosomal activities of selected cationic diphenylisoxazoles provided 
the basis of synthesis of a series of 60 cationic 1,4-diphenyl-1H-1,2,3-triazoles [44] (Figure 
14  a–d) by Tidwell RR  et  al. The 1,2,3-triazole fragment was used because it  was  a 
suitable isosteric replacement for the central five-membered ring of furamidine [45–55] and 
also because 1,4-diphenyl-1,2,3-triazoles showed geometrical resemblance to furamidine. 
It was observed that the cytotoxicities of triazoles were as  lower compared to that of 
pentamidine and were  not affected by the alkylation on the amidine groups or the 
substitution on the aromatic rings. However, the placement of the cationic moiety in the 
4-position increased the cytotoxicities of diamidines 46 (Figure 15) with respect to the 
pentamidine.  Except few, majority of unsubstituted diamidines exhibited higher in vitro 
activities against T. brucei rhodesiense than bis(N-isopropyl)amidines and diimidazolines. 
The compounds with cationic fragments in the 5,5'-position (compounds 1–15, Figure 14a) 
of the aromatic rings were in most cases less potent against T. brucei rhodesiense than 
isomers bearing at least one cationic moiety in the 4- or 4'-position (compounds 16–60, 
Figure 14b–d). However compound 46 (Figure 15) with dicationic moiety at 4,4' position 
showed excellent in vitro activity (0.004 µM). The introduction of the hydroxy group in the 
2-position of the phenyl ring significantly reduced activities and increased the cytotoxcity 
against T. brucei rhodesiense because of the formation of the intramolecular hydrogen 
bond between the hydrogen atom of the 2-hydroxy group and the 2-nitrogen of the triazole 
ring. The in vivo analysis of compound 46 showed that when administered at 4 × 5 mg/kg, 
4 × 1 mg/kg and 1 × 10 mg/kg by the intraperitoneal route it cured all the infected animals 
in the acute mouse model of African trypanosomiasis.  
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Fig.14.  The basic nucleus and position of the various substitution used for synthesis of 
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Thus promising in vitro and in vivo anti-trypanosomal activity of cationic 1,4-diphenyl-1H-
1,2,3-triazoles derivatives and in particular compound 46 necessitate further investigation 
of this class of compounds as potential anti-trypanosomal drug candidates.  
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Fig. 15.   Most active compound 46 of the series with promising anti-trypanosomal 
properties 
Comparision of isoxazole and triazole derivative of furamidine 
The replacement of central furan ring of furamidine either by isoxazole or 1,2,3-triazole 
resulted into compounds with better activity than that of furamidine. Position and the 
nature of the cationic substituent governed the anti-trypanosomal activity of the two series. 
In general the para substituted diamidines in both the series were the most promising 
compounds with good activity.  Thus these compounds should be further evaluated to 
produce better analogue of furamidine 
Bis(2-aminoimidazoline) and Bisguanidine 
The recent report on N,N'-bis(4-amidinophenyl)piperazine (Figure 16), which was shown to 
be  very effective in vivo  anti-trypanosomal agent has attracted the interest in this 
compound  [56].  Hence  in search for new HAT chemotherapy Dardonville  C  et al  [57] 
decided to carry out an in vitro screening of a total of 62 compounds against the parasite 
T. brucei rhodesiense taken from their in-house library. Based on this they showed that 
bisguanidine and especially bis(2-aminoimidazoline)diphenyl compounds displayed potent 
anti-trypanosomal activity in vitro and vivo against T. b. rhodesiense, the causative agent 
of acute HAT [58, 59]. Among the 62 compounds screened, compounds1c, 28b, 32b and 
41b (Figure 17) showed excellent in vitro  activity  (49nM,  69 nM,  22 nM  and  118 nM 
respectively) as well as high selectivity (>5294, 3072, 29.5 and 881respectively) for the 
parasite. These studies revealed that compounds bearing 2-aminoimidazoline cations had 
higher selectivity for the parasite and similar activities with respect to their guanidine 
counterparts. In addition, a correlation between anti-trypanosomal activity and DNA 
binding affinity was observed, suggesting a possible mechanism of action for these 
compounds. Those molecules that showed an excellent in vitro activity as well as high 
selectivity for the parasite represent new anti-trypanosomal lead compounds.  
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In light of these promising results, bis(2-aminoimidazoline) derivatives deserve more 
investigation as anti-trypanosomal agents and DNA minor groove binders. The synthesis 
and study of new derivatives and prodrugs of these lead compounds is ongoing. 
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Fig. 17.   Structures of compounds that showed excellent in vitro activity and selectivity 
Other target and lead compounds 
Progress has also been made on targets other than DNA minor grove. In addition to newer 
targets some new lead compounds  have  also been identified with proper anti-
trypanosomal activity but uncertain mechanism of action. 
Trypanothione Reductase Inhibitors 
The enzyme trypanothione reductase (TR) which restores the oxidized trypanothione to 
reduced state has evolved as an effective drug target. Many inhibitors of this enzyme have 
been developed but most of them combat  with problems related to bioavailability, 
pharmacokinetics and metabolism. Despite this quinolines have evolved as most important 
class of compounds against TR due to  their  broad spectrum of activity, excellent 
pharmacological and pharmacokinetic properties such as high plasma levels, high 
clearance, oral and parenteral applicability, chemical stability and rare side effect.  
In view of this Gilbert IH [60] reported the screening of 62000 compound libraries against 
T. brucei. High through put screening (HTS) which resulted into identification of two novel 
compound series active against the enzyme trypanothione reductase. Series 1 was based 
on the quinoline scaffold (Figure 18a) in which compound 2 (Figure 19a) with methylfuran 
group at R
3 position, Br at 6
th position of quinoline ring and N-methylethanamine group at 
R
1 position was the most potent and significant TR inhibitor with TR inhibitory activity of 
1.1 µM. According to SAR study the replacement of methylfuran with other groups like 
furan, phenyl, pyridinyl, thiophene led to decrease in activity. Also the replacement of Br 
with H or F reduced the activity while Cl group retained the activity. At 4
th position the NH 
and NMe groups were equally active. The alkylamines at R
1  were active whereas the 406  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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simple alkyl or aryl groups led to inactive compounds. The second series was based on 
the pyrimidopyridazine scaffold (Figure 18b), in which the compound 49 (Figure 19b) 
showed promising inhibitory activity of 2.6 µM. In case of series 2 replacement of methyl 
group at R
1 position by H led to the decrease in activity. At R
2 position methyl and ethyl 
group showed activity while the H and chain extensions to propyl, butyl and cyclopentane 
led to decrease in activity. Substituted phenyl and alkenylphenyl group at R
3 position gave 
the most active compound of the series. Thus these quinoline compounds with promising 
activity could serve as lead compounds for further development of targeted drugs against 
African trypanosomiasis. 
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Fig. 18.   Two novel series active against the enzyme trypanothione reductase 
In addition to this synthetic optimization study based on the lead anti-trypanosomal 
compound 1,2-dihydro-2,2,4-trimethylquinolin-6-yl 3,5-dimethoxybenzoate (Figure 20) was 
undertaken by Werbovetz KA et al [61] in an attempt to discover new trypanocides with 
potent in vivo activity targeting TR enzyme. In course of this a total of 53 compounds were 
evaluated in vitro for their anti-trypanosomal activity and cytotoxicity. The compounds with 
oxygen atom at 6
th position were the most active compounds in the series, for example 
compound 9 (Figure 21) showed better anti-trypanosomal activity (0.007 µM) and low 
cytotoxicity (6.8 µM) than melarsoprol (IC50 = 0.008µM and cytotoxicity = 7.9µM). Whereas 
compounds lacking the 6-oxygen atom or bearing an oxygen atom at the 7-position rather 
than the 6- position were far less potent than those containing an alcohol or acyloxy group 
at the 6-position. Compounds carrying aliphatic or a 2-phenylacetyl ester side chains were 
as potent and selective as their benzoylated or acetylated counterparts. However 
compound 9a was unstable due to auto-oxidation, so the unstable alcohols were esterified 
to generate prodrug 10a (Figure 21) having promising activity of 0.014µM against these 
parasites and a selectivity index of 1700. The in vivo evaluation of compound 10a in a 
murine model of African trypanosomiasis showed good results as the prodrug extended 
the lifespan of mice infected with T. b. brucei.  
Thus compound 10a can serve as lead compound for further investigation of this class of 
molecules as potential candidates against HAT. Efforts are also be undertaken to further 
elucidate the metabolism, pharmacokinetics, and the anti-trypanosomal mechanism of 
action of this novel and promising class of compounds.   Neglected Disease – African Sleeping Sickness: Recent Synthetic and Modeling Advances  407 
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Fig. 20.   Lead anti-trypanosomal compound 1,2-dihydro-2,2,4-trimethiquinolin-6-yl 3,5-di-
methoxybenzoate 
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Fig. 21.   Compound 9a and its prodrug 10a having promising anti-trypanosomal 
properties 
Topoisomerase inhibitors 
DNA  topoisomerases have evolved as an effective drug target in prokaryotic and 
eukaryotic systems as these enzyme  mediate mechanistic interactions such as 
supercoiling, relaxation, knotting or catenating of DNA double helices.  Based on their 
mechanism of action, topoisomerases can be classified as type I enzymes, which break a 
single strand of the DNA helix during the catalytic cycle, and type II enzymes, which make 
double-stranded breaks. On the basis of primary sequence and reaction mechanism, type 
I topoisomerases are further subdivided into type IA and type IB. 
Recently Shapiro TA et al [62] evaluated the activity of indenoisoquinolines (Figure 22), 
originally known to have anti-cancer activity, against T. brucei and found that most of the 
compounds showed in vitro activity at submicromolar concentrations. The compound 12 
(Figure 23) with propylamino group at R
6 position and methoxy group at R
2, R
3 and R
9 was 408  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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the most active one with in vitro anti-trypanosomal activity of 0.05 µM. The compound also 
showed good in vivo activity as it delayed parasitemia and extended survival in infected 
mice. According to structure-activity analysis the compounds with enhanced potency 
included  alkylamino substitutions on N-6, methoxy groups on C-2 and C-3, and a 
methylenedioxy bridge between C-8 and C-9. Testing of indenoisoquinolines with 
promising activity on L1210 mouse leukemia cells revealed all the compounds were more 
effective against trypanosomes than against mammalian cells. The indenoisoquinolines 
also showed appreciable water solubility indicating that these compounds have good 
quality for drug development. These compounds showed their anti-trypanosomal action by 
multiple mechanisms. The study indicated that they stabilize topoisomerase-DNA 
complexes in situ and may also impede topoisomerase binding to DNA. These agents 
markedly inhibited DNA synthesis by interfering with topoisomerase and possibly other 
DNA-metabolizing enzymes.  
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Fig. 22.   The indenoisoquinoline scaffold. Structure-activity analysis was performed with 
substitutions at the numbered positions 
Thus multiple mechanisms of action of these compounds against trypanosomes are an 
attractive feature, since such compounds are less prone to drug resistance. Therefore 
indenoisoquinoline compound 12 is a promising lead for the development of drugs against 
sleeping sickness. 
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Fig. 23.   Lead compound 12 with promising in vitro and in vivo activity 
In addition Burri C et al [63] tested about 160 fluroquinolones and their derivatives which 
are specific inhibitors of topoisomerases, against cultured bloodstream forms of T. b. 
rhodesiense. The modifications in the quinolone core nucleus (Figure 24) led to 
characteristic in vitro activity and toxicity. The metal quinolone UL 5 (Figure 25a) with F 
group at the position 6 and piperazin at R
7 position was the most potent compound with 
IC50 values of 100 ng/ml. DW 271 (Figure 25b), thiazolopyrazine incorporated tetracyclic 
quinolines Kanebo 8g and Kanebo 8h (Figure 25c), and the two sulphanyl fluoro-
quinolones N (CH3)2SNx and OCH3SNx (Figure 25d) were also active, with IC50   Neglected Disease – African Sleeping Sickness: Recent Synthetic and Modeling Advances  409 
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concentrations in the range of 300 ng/ml up to 900 ng/ml. Some of the DuPont 
compounds, developed as anti-tumour drugs, were highly active but also showed high 
cytotoxicity on HT-29 cells. It was observed that the position R
1 and position R
2 in the 
quinolone core nucleus was not prerequisite for anti-trypanosomal activity and also 
substitution at R8 position was not necessary for trypanocidal activity. Thus, based on the 
result obtained from SAR analysis special attention should be given to R
7 position and the 
tetracyclic derivatives. The in vivo results of these compounds were very poor, as none of 
the compounds evaluated produced cure of mice in dose  escalation experiment up to 
100mg/kg i.p. However no signs of toxicity were observed during the experiments. The in 
vivo ineffectiveness had not been explained and no drug level determination in the plasma 
of the treated mice was performed. 
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Fig. 24.   Basic chemical structure of fluoroquinolones 
Despite these failures, this class of compounds is very attractive for further search for 
trypanocidal compounds because of complete lack of any toxic signs at all dosage levels 
tested in vivo. 
Polyamine metabolism inhibitors 
Polyamines are generally involved in growth and differentiation [64–67] within the cell and 
their analogs are also used as anticancer agents, antiparasitic agents, antidiarrhoeals, 
anti-HIV agents, metal chelators, and gene delivery agents. Since the inhibition of the 
initial polyamine biosynthesis enzyme, ornithine decarboxylase, by DL-α-difluoromethyl-
ornithine (DFMO) is toxic to African trypanosomes cells, [68, 69] polyamines can become 
a promising anti-trypanosomal compound. 
DFMO [70–72] is the most recently developed agent for late stage T. b. gambiense and T. 
b. brucei sleeping sickness, but has  not  been  active against all strains of T. b. 
rhodesiense. The major drawbacks of DFMO are its cost, the duration of treatment and its 
availability. Recent clinical studies have investigated that DMFO can be used in 
combination with clinically used trypanocides including suramin, nifurtimox and 
melarsoprol [73, 74]. These combinations result in significant reduction in DFMO dosage 
and time of administration. Initial clinical study has shown that DFMO + nifurtimox are 
superior to DFMO + melarsoprol and melarsoprol + nifurtimox. The DFMO + nifurtimox 
regimen (NECT regimen) allowed reduction in DFMO regimen from 14 to 7 days  (56 
versus 28 infusions) with a 94% cure rate and are associated with significantly reduced 
adverse side effects as compared to melarsoprol-based therapy. The success of the 
combined regimen has been most likely due to ability of DMFO to reduce trypanothione 
levels and resistance to oxidative stress and the ability of nifurtimox to generate oxidative 
stress.  410  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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Fig. 25.   Most promising compounds of quinolone derivatives 
In addition to DFMO, a number of other agents targeting polyamine metabolism have 
shown promise. These include MDL 73811 (5'-{[(2Z)-4-aminobut-2-en-1-yl](methyl)amino}-
5'-deoxyadenosine), an enzyme-activated inhibitor of S-adenosylmethionine (AdoMet) 
decarboxylase which supplies decarboxylated AdoMet, the source of aminopropyl groups 
for spermidine and spermine synthesis [75]. 
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Recently Gilbert et al [76] designed, synthesized, and evaluated substituted polyamines, 
carrying 1,3,5-triazine units, as potential anti-trypanosomal drugs. Preliminary results 
indicated that this route might be successful, and lead structure A (Figure 26) was used as 
a starting point for the synthesis of two series of analogues. In the first series, the influence 
of structural changes of the central core unit was investigated while in the second series, 
the effect of additional methyl substituents on the 1,3,5-triazine was studied. The 
compounds were designed with the intention to selectively target the interior of T. brucei 
via the P2 amino-purine transporter. In the first series the compound containing the n-
dodecyl chain as core unit, showed weak activity against  T. b. rhodesiense. The 
compound with n-nonyl chain was the most promising compound and its various 
analogues were designed by replacing NH2 groups on the triazine ring with NHMe and 
NMe2 groups. Introduction of one or two methyl groups per triazine unit resulted in a 10-
fold increase in anti-trypanosomal activity. When four methyl groups per triazine unit were 
introduced, an 80-fold increase in activity was observed. Similarly, replacement of NH2 
group in n-dodecyl chain led to 2–20-fold higher anti-trypanosomal activity for the 
methylated derivatives. Monosubstituted compounds showed a slight increase in activity 
against T. b. rhodesiense as compared to the disubstituted compounds. The methylamino 
substituted triazines attached to the C9- (compound 8c, Figure 27) or C12-(compound 8f, 
Figure 27) polyamine precursor via an additional CH2  linker resulted in most active 
trypanocidal compounds(IC50 of 8c = 0.27µM and 8f = 0.18 µM). Beside good activity, the 
compounds showed poor in vivo activity producing no cure to the infected mice and 
concentrations greater than 10 mg kg
−1 induced severe acute toxicity.  
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Fig. 27.   Tetra triazine substituted polyamine compounds 
The actual mode of action for the reported triazine substituted polyamines remains 
unclear. So to understand and improve the activities of these compounds, further research 
has to verify intracellular drug targets and possible metabolic pathways. 
AdoHcy hydrolase inhibitors  
Stanislaw FW et al [77] have reported the anti-trypanosomal activity of 5'-deoxy-5'-(E)-
(iodomethylene)adenosine, which is a known inhibitor of AdoHcy hydrolase, [78, 79] and 
the synthesis and inhibition of T. brucei by a series of 6-N-cyclopropyladenosine 412  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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analogues modified at carbon-5'  including halomethylene, acetylenic, and oxime 
derivatives.  
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Fig. 28.   (a) structure of 5'-deoxy-5'-(E)-(iodomethylene)adenosine  
(b) structure of 6-N-cyclopropyl-5'-deoxy-5'-(E)-(iodomethylene)adenosine 
The 5'-deoxy-5'-(E)-(iodomethylene)adenosine (EIDDHA) and its 6-N cyclopropyl analogue 
(Figure 28a, b) have shown promising in vitro inhibitory activity (IC50 at 9 and 12 μg/mL) 
against  T. brucei. The utilization of adenosine analogues as anti-parasitics should be 
explored as a therapeutic paradigm, as it has been shown previously that inhibitors of 
AdoHcy hydrolase are also very potent inhibitors against the growth of Plasmodium 
falciparum [79]. This class of 6-N-cyclopropyl adenosine analogues modified at carbon 5', 
does not exhibit an inhibitory effect on human or parasite forms of the enzyme and 
displays only marginal antiviral activity in comparison to analogues which have been 
unmodified at 6-amino position (that are potent inhibitor of AdoHcy hydrolase). Therefore 
these compounds require further structural modification in order to develop newer 
analogues with improved activity against T. brucei. 
New 4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine derivatives 
The synthesis of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl] morpholine derivatives by 
Perozzo R et al [80] resulted in to the discovery of newer class of anti-trypanosomal 
compounds having stage specific action, as these compounds have shown moderate to 
very good activity against the blood stage of T. b. rhodesiense.  The two compounds, 
4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine  (1.0µM)  (Figure 29a) and 
1-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]piperazine  (1.1 µM) (Figure 29b) with a pyrazol 
ring, are the most potent anti-trypanosomals of the series and have same cytotoxicity (61.6 
µM), indicating that the pyrazol ring is very important for anti-trypanosomal activity. The 
substitution of pyrazol ring with isoxazole derivative leads to a six fold reduction in activity 
as compared to the most potent compound. In addition, substitution with nitrophenyl or 
aminophenyl also results in strong reduction in activity.  The  phenoxy ring in the 
compounds is also important for activity as replacing it by an ethylene group results in nine 
fold reduction in efficacy. Further substitution with a nitro group or an amino group reduces 
potency up to 4-fold or 18-fold respectively. The stage specific action of these compounds 
is unknown. Further optimization of this class of compounds is required in order to lower 
the cytotoxicity profile of the compound.   Neglected Disease – African Sleeping Sickness: Recent Synthetic and Modeling Advances  413 
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(a)
4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine
O
NH N
N N
H
(b)
1-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]piperazine  
Fig. 29.   The most active compound of morpholine series 
Glutathione derivatives 
In vitro evaluation of a series of N-, S-, and COOH-blocked glutathione derivatives have 
been  carried out  by D'Silva and  Daunes  [81]  against bloodstream  form  Trypanosoma 
brucei trypomastigotes, to identify the determinants necessary for activity and for further 
development into an active lead structure. The results shows that N, S-blocked glutathione 
diesters are the most active inhibitors of T. brucei parasites and that N-acetyl-S-benzyloxy-
carbonylglutathione dimethyl ester (compound 5) and the N,S-benzyloxycarbonyl-S-2,4-
dinitrophenylglutathione diester derivatives (compounds 17–19 & 21) (Figure 30) represent 
lead structures possessing minimal toxicity which potentially could be developed further to 
yield a therapeutically active agent for the treatment of trypanosomiasis. 
Prodrug approaches 
Pentamidine, furamidine and its analogues lack oral bioavailability  [82, 83].In  addition 
several analogues of furamidine show excellent activity on intravenous dosing but are 
ineffective on oral administration [83, 84]. Generally, oral administration is the preferred 
dosing regime, and hence, prodrug strategies for diamidines that have the potential to 
overcome their limited oral bioavailability merit attention. The following works have been 
performed by Boykin DW et al to develop prodrugs. 
O-Alkoxyamidine Prodrugs of Furamidine 
Boykin DW et al [85] syhthesized and evaluated five O-alkoxyamidine analogues of the 
prodrug 2,5-bis[4-methoxyamidinophenyl]furan against Trypanosoma brucei rhodesiense 
in the STIB900 mouse model by oral administration. It was observed that the size of the 
O-alkyl side-chain determined the metabolic stability of the prodrugs. The prodrugs with 
the O-methyl analogue were most susceptible to metabolism while the larger O-n-butyl 
and O-n-hexyl groups were least susceptible to metabolism. The in vivo studies in the 
STIB900 mouse model for T. b. rhodesiense showed that compounds with an O-methoxy-414  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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amidine or O-ethoxyamidine group effectively cured all trypanosome-infected mice, 
whereas prodrugs with larger side-chains did not completely cure the mice. Therefore the 
O-alkoxyamidine prodrugs, where the alkyl chain is less than three carbons, could 
effectively be used as prodrugs for amidines. 
N
H
N
H
N
H
R
4
R
2
R
3
O
NH
S
R1
O
NH
Compound 5:   R
1 = BrBz, R
2 = H, R
3, R
4 = NH2  
Compound 17:   R
1 = 2,4-DNP, R
2 = Cbz, R
3, R
4 = OMe
Compound 18:   R
1 = 2,4-DNP, R
2 = Cbz, R
3, R
4 = OPr 
Compound 19:   R
1 = 2,4-DNP, R
2 = Cbz, R
3, R
4 = OBu 
Compound 21:   R
1 = 2,4-DNP, R
2 = Cbz, R
3, R
4 = OHx 
 
Fig. 30.   N,S-blocked glutathione diesters 
Aza-Analogues of Furamidine 
Boykin DW et al [26] have also prepared aza-analogues of furamidine that exhibit high in 
vitro  activity against T. b. rhodesiense. Several prodrugs of these aza-analogues (8c) 
(Figure 31) show excellent oral activity in vivo  which is superior to that of furamidine, 
2,5-Bis[4-(methoxyamidino)phenyl]furan and 2,5-bis[4-(N-hydroxyamidinophenyl]furan 
against  T. b. rhodesiense  in this mouse model. They have  found several excellent 
candidates for further evaluation against T. b. rhodesiense. 
N O
NH
NH2
N H2
N H
 
Fig. 31.  Compound 8c 
Terphenyl Diamidines and Analogues 
In addition to above mentioned prodrug synthesis Boykin DW et al [86] also reported that 
bis-amidoximes and bis-O-alkylamidoximes of a number of diamidine systems are 
effective prodrugs. In order to develop orally effective anti-trypanosomal agents, they 
synthesized these two types of potential prodrugs in the terphenyl series. It was found that 
compound 10b and 10d (Figure 32) showed good activity in the range of 2 nM. Among 
these compounds 10b had lower cytotoxicity (6.4μM) profile but had very poor in vivo 
activity (cured none of the infected animal in STIB900 mouse model). Whereas compound 
10d showed excellent in vivo  activity, by curing all the infected animals upon oral 
administration in STIB900 mouse model. To capitalize on the efficacy of these potent   Neglected Disease – African Sleeping Sickness: Recent Synthetic and Modeling Advances  415 
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dications, other prodrugs that rely on different bioconversion pathways need to be 
developed. 
Compound 10b:  R = H, R
1 = F, R
2 = nil, X = CH, Y = CH, M = CH 
Compound 10d:   R = H, R
1 = H, R
2 = nil, X = CH, Y = N, M = CH 
Y
X
M M
R
1
R
2
N R
NH2
N R
N H2
 
Fig. 32.   Terphenyl diamidines and analogues 
Fused ring dicationic compounds and their prodrugs 
Boykin DW et al [87] showed that some of the dicationic guanidine, N-alkylguanidine, and 
reversed amidine derivatives of fused ring systems have good in vitro activity against 
Trypanosoma brucei rhodesiense  [87, 88].  The dicationic N-isopropylguanidino-9H-
fluorene (12c, Figure 33) showed promising in vivo biological results by giving 4/4 cures of 
the treated animals in the STIB900 animal model for African trypanosomiasis. In addition 
the N-methyl analogue (12a, Figure 33) also showed high activity giving 3/4 cures of the 
treated animals in the STIB900 animal model for African trypanosomiasis. In order to 
enhance the oral bioavailability, two novel classes of potential guanidine prodrugs were 
prepared. The N-alkoxyguanidine derivatives 12d and 12e (Figure 33) were not effective 
as prodrugs. Whereas the carbamate prodrugs (11c, Figure 33), gave promising results 
with 4/4 cures on oral administration in the STIB900 mouse model. The result showed that 
these compounds bind strongly to the DNA minor groove, but despite strong bonding 
these compounds do not have high antiparasitic activity.  
Compound 11c:   A = NH(C=NCO2Et)NHMe, Y = CH2 
Compound 12a:   A = NH(C=NH)NHMe, Y = CH2 
Compound 12c:   A = NH(C=NH)NHiPr, Y = CH2 
Compound 12d:   A = NH(C=NOMe)NH2, Y = CH2 
Compound 12e:   A = NH(C=NOiBu)NH2, Y = CH2 
Y A A
 
Fig. 33.   Fused ring dicationic compounds and their prodrugs 
Computer-assisted drug design (CADD) approaches 
As compared to the last 15 years,  there has been a revival of drug research and 
development regarding neglected parasitic diseases, and a number of drug development 
projects are currently ongoing. However discovering lead compounds with anti-416  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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trypanosomal activity remains a crucial step to sustain the progress achieved till date. The 
use of Computer-assisted drug design (CADD), since their start, has become increasingly 
helpful in understanding many aspects of chemical-biological interactions in drug and other 
scientific research. The latest technological advances (QSAR, structure-based design, 
ligand-based design, cheminformatics & bioinformatics) are providing a much improved 
basis for the design of ligands and inhibitors with desired specificity. Recently, computer-
assisted drug design approaches based on ligand-based and structure- based drug design 
have been successfully employed to develop new drugs for the treatment of cancer, AIDS 
and other diseases  [89–96].  QSAR  [97]  has been widely used for years to provide 
quantitative analysis of structure and activity relationships of compounds.  Statistical 
methods are applied in QSAR modeling to establish correlations between chemical 
structures and their biological activities. Once validated, the findings can be used to predict 
activities of untested compounds. Though only countable but sustainable attempts has 
been made to build molecular  model in the field of HAT, exemplified by the work of 
Prashanth A et al [98] who have performed 3D QSAR analysis on a library of heterocyclic 
diamidines derivatives with antiparasitic activity and Martin MB  et at  [99]  who have 
performed CoMFA analysis on bisphosphonates against Trypanosoma brucei 
rhodesiense.  
Prashanth A et al have  performed CoMFA and CoMSIA based 3D QSAR analysis on 
furamidine and a set of 25 other structurally related compounds. The main goal of this 
study has been to correlate the structural features of this class of compounds with their 
biological activity using the knowledge of the DNA minor groove bioreceptor in AT 
sequences.  
Two different alignment strategies, based on a putative kinetoplast DNA minor groove 
target, have been used. Due to conserved electrostatic properties across the compounds, 
models that used only steric and electronic properties have  not performed  well in 
predicting biological results. An extended CoMSIA model with additional descriptors for 
hydrophobic, donor, and acceptor properties have had  good predictive ability with a 
q
2 = 0.699, r
2 = 0.974, SEE, standard error of estimate = 0.1, and F = 120.04. The results 
have been used as a guide to design compounds that, potentially, have better activity 
against African trypanosomes. 
These specifically derived chemical properties that are important to activity and in view of 
this, the developed model can be adopted as a rational approach toward the selection of 
substituents at various positions in the scaffold. The information can be used to predict 
new compounds for synthesis that have high probability of enhanced activity. 
Martin  MB  et at have been  the first to provide evidence that the enzyme farnesyl 
pyrophosphate synthase is a principal site of action of the bisphosphonate risedronate in 
inhibiting the growth of bloodstream-form T. b. rhodesiense trypomastigotes, the causative 
agent of human East African trypanosomiasis. They have also reported 3D-QSAR/CoMFA 
analysis of 26 bisphosphonates, yielding a theoretical-versus-experimental pIC50 
correlation of R
2 = 0.87 with a cross-validated R
2 value of 0.79. This has been the first 
report of a QSAR/CoMFA correlation for 1,1-bisphosphonates acting as antiparasitic 
agents.  These results should be of use in the design and further development of 
bisphosphonates as antiparasitic agents.   Neglected Disease – African Sleeping Sickness: Recent Synthetic and Modeling Advances  417 
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Daunes and D'Silva [100]  have  performed QSAR analysis in order to derive the 
contribution of Log P and Es to the in vitro antiprotozoal activity of glutathione derivatives. 
Analysis of the inhibition data (ED50) vs calculated log P and Es values provided evidence 
to support membrane penetration and steric factors as the key component in the activity of 
these compounds. The optimum values for log P and Es determined have been 5.8 and 
−0.70, respectively. The best linear QSAR equation derived by a process of elimination, 
using a set of 17 compounds, excluding the outliers is eq 1 with an R
2= 0.84 and F= 12.0 
(1)   102     W 0.002     MW   0.20     Es 1.87     log 57 . 2 ) (1/ED   Log 50 − − + + − = P  
Equation 1 indicates that the therapeutic activity of these compounds decreases with 
increasing values of log P and Es. 
Our core research group has also performed QSAR analysis of dicationic 
diphenylisoxazoles [10]. In this  study, attempt has been to investigate the relationship 
between the various physiochemical parameters and anti-trypanosomal activity of 
dicationic 3,5-diphenylisoxazoles that may be helpful in development of potent anti-
trypanosomal agents against sleeping sickness.  
Several statistical expressions have been  developed using stepwise multiple linear 
regression analysis (MLR) and partial least squares (PLS). The best MLR model showed 
good correlative and predictive ability as shown in following equation 
1.0970852     X   9 0.09010428   X   0.32909143   X   7 0.02356663   Y 3 2 1 − − − − =  
Where X1=cosmic energy, X2=Log P, X3=total lipole. 
s value=0.31, F value=79.01, r=0.94, r
2=0.88, r
2cv=0.84 
A comparable PLS model with r
2
cv=0.84 has also been obtained. The developed model 
has been validated by leave-one-out method of cross-validation and prediction of test set. 
The study indicates that the anti-trypanosomal activity is largely  explained by cosmic 
energy, log P and total lipole descriptors. The QSAR study has reported in present study 
provides important structural insights, related to anti-trypanosomal activity. Authors have 
developed a validated and highly predictive model sharing important structural requirement 
for effective binding of anti-trypanosomal compounds to minor groove of T. b. rhodesiense 
DNA.  The  model reported in the study  should  be helpful in development of new 
compounds with improved efficacy and oral bioavailability. In line to the developed model 
authors have also designed some molecules which showed good activity in silico. The 
further study of these compounds is in progress. 
Conclusion 
The poor pharmacokinetic profile and toxicity produced by the drugs currently used to treat 
trypanosomiasis requires an immediate attention for the development of safe, economical 
and high affinity chemotherapeutic agents to meet the need for this class of drugs. The 
unacceptable truth is the lack of attention of the government and less interest of 
pharmaceutical companies in light of less monitory gain in the area of protozoal infection 418  S. K. Paliwal, A. N. Verma, and S. Paliwal:   
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since most of the affected people belong to poorer country. Surprisingly the endeavors of 
different research group discussed in this review belong to academic institutions. It is felt 
by the researchers  that the treatment for HAT requires a combined approach by 
government organization, pharmaceutical companies and academic institutions. The most 
promising fact is that in the last decade several synthetic approaches have been made in 
the field of development of anti-trypanosomal therapies. Several compounds are being 
synthesized that yield new compounds for the treatment of HAT,  as a result of these 
synthetic approaches newer leads have been identified, which are under different phase of 
drug development.  
The promising in vitro and in vivo activities of dicationic molecules clearly indicate that 
aromatic diamidines are the most promising class of compounds for the development of 
newer drugs against HAT. The most important one is the newer analogous of existing 
drugs pentamidine (compounds 32, Figure 3e and 66, Figure 3b) which shows excellent in 
vivo  and  in  vitro  activity  (0.004  and  0.001  μM  respectively)  and  also  has  very good 
selectivity index against the parasite but is cytotoxic. In an attempt to synthesise newer 
compounds with reduced cytotoxicity than pentamidine molecules, several benzofuran 
derivatives have been synthesized. However the replacement of phenoxy fragement of 
pentamidine with a benzofuran motif has  resulted  in poor analogues with lower anti-
trypanosomal activity but improved cytotoxic profile. However the strong activity against T. 
b. rhodesiense isolates indicates that steps should be taken to initiate further studies of 
compound 66 and compound 32 which can be further evolved as new lead compound. 
The newer analogues of furamidine also show promising anti-trypanosomal activity along 
with lower cytotoxicity than furamidine. Thus strong activity against T. b. rhodesiense and 
lower cytotoxicity of compound 3 (Figure 13b) indicates that these compounds should be 
further evaluated. Thus the DNA minor grove binders are still the most interesting and 
potential target for the development of newer anti-trypanosomal agents. 
Apart from diamidines,  polyamines and guanidine also have  the potential to give anti-
trypanosomal compounds. The success of DMFO as polyamine inhibitors has attracted 
researchers  for synthesis and development of agents targeting polyamine metabolism. 
Recently polyamines carrying 1,3,5-triazine units have been synthesized and evaluated 
against T. brucei. These compound exhibited good activity but are cytotoxic. Morpholine 
and dihydroquinolines have  also shown promising in vivo anti-trypanosomal activity. In 
addition to this development of prodrugs, the existing compounds also promise to address 
the pharmacokinetic related problems, in near future.  
Thus excellent in vitro and in vivo activities and high selectivity of aforementioned 
compounds merit further investigation in order to reduce the cytotoxicity that may result in 
development of newer anti-trypanosomal drug with reduced toxicity, improved efficacy and 
pharmacokinetic profile. As the drug discovery and development process is expensive in 
terms of time and money, the cross application of existing series of compounds with 
selective trypanocidal activity may be the best prospect to new anti-trypanosomal drugs in 
the short term. More emphasis has to be put in the field of CADD approaches for 
development of anti-trypanosomal agents as CADD study reduces the time and cost 
required for development of newer analogues. 
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